Tests ultrasound opening the blood-brain barrier with standard treatment for newly diagnosed glioblastoma
Tests ultrasound brain barrier opening plus standard treatment in adults with new glioblastoma.
Key facts
- Who runs it
- Assistance Publique Hopitaux De Paris
- Where
- Angers, ANGERS, Bordeaux Cedex, Bron, Marseille, Paris, and Suresnes, FranceSee the 7 sitesAlso in 1 other country, 1 site
- Registry title
- Multisite open-label randomized phase II clinical trial in newly diagnosed glioblastoma treated by concurrent TemoRadiation and adjuvant temozolomide +/- ultrasound-induced blood brain barrier opening - SonoFIRST
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 63 people, planned
- Started
- 11 Sept 2021
- Planned end
- 11 Mar 2026
- Type of study
- Interventional, 2 groups
- Record updated
- 5 December 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a newly found glioblastoma (IDH wild-type) who can have surgery and the standard treatment with radiation and temozolomide. It tests adding ultrasound opening of the blood-brain barrier.
- Age
- 18 years or older. For people over 70, the neuro-oncology tumor board must approve joining.
- Sex
- All sexes can join.
- Disease stage
- Newly diagnosed, suspected IDH wild-type glioblastoma above the tentorium (supratentorial). The tumor shows up on T1W MRI and is 7cm (2.8 in) or smaller. It can be partly or fully removed by surgery.
- Earlier treatment
- No investigational drug within 30 days before joining. Other prohibited treatments include antibiotics known to harm nerves, drugs that may harm the brain once the barrier is opened, and non-absorbable material in the brain (such as dura substitute).
- Biomarker or test result
- The tumor is suspected to be IDH wild-type on brain MRI. No other marker is asked for.
Main reasons for not taking part
- Several tumors, unless all lie within a 70 mm area the ultrasound can reach, or a tumor in the posterior fossa
- Uncontrolled epilepsy or uncontrolled pressure inside the skull
- Pregnant or breastfeeding women
- Known brain aneurysm, or implants such as clips, shunts or stents that cannot be removed
- Serious heart, lung, kidney or liver disease, or an immune deficiency such as HIV
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Brain MRI with suspicion of newly diagnosed IDH wild type GBM
- Supratentorial tumor
- T1W Tumor enhancement of ≤ 7cm
- Eligible for partial or complete surgical resection and for concurrent TemoRadiation followed by adjuvant TMZ (according to Stupp protocol) with or without Tumor Treating Fields* - (*Tumor Treating Fields is applicable only in participating centers in France)
- Patient ≥ 18 years, able and willing to give signed and informed consent. Inclusion for patients aged >70 years should be validated in neuro-oncology tumor board (RCP)
- KPS ≥70
Who cannot take part
- Patients with known intracranial aneurism, with and/or unremovable coils, clips, shunts, intravascular stents, wafer, non resorbable dura substitute, or reservoirs
- Patients with an uncontrolled intercurrent illness or any pre-existing comorbidities that in the Investigator’s opinion may prevent the implantation of the device or may impair the ability of the patient to receive treatment with SonoCloud or may be cofounding for evaluation of the clinical trial
- Patients with any following prohibited treatments: • Any investigational medicinal product within 30 days prior to inclusion and during the study • Antibiotics with known neurotoxicity (eg, aminoglycosides, cephalosporin, quinolones), unless substitution is not possible, • Non-absorbable material (dura matter substitute, hemostatic agent…) • Any other drug according investigator to cause cerebral toxicity due to BBB opening • Contra-indications to temozolomide
- Implantation of the SC-9 not possible according to neurosurgeon (Any patient morphological characteristics (e.g. skin thickness >9mm), which, from neurosurgeons’ opinion, prevent implantation of the device or may impair the ability of the patient to receive treatment with SonoCloud, would be excluded); Contra indication Optune: If TTF treatment is initiated (only available in France), the investigator must first ensure that the patient has no contraindications to the Optune device (See page 41)
- Patients with the following are not eligible: • Known arterial hypertension grade 3 or higher without adequate control on medications • Known or suspected unstable active or chronic infections requiring systemic treatment • Known significant cardiac disease: right-to-left shunts, Unstable angina pectoris, Symptomatic congestive heart failure, Unstable cardiac arrhythmia • Known significant pulmonary disease: severe pulmonary hypertension (pulmonary artery pressure > 90 mmHg), uncontrolled systemic hypertension, adult respiratory distress syndrome, or Pneumonitis • Known Severe renal failure • Known serious myelosuppression • Known Psychiatric illness/social situations that would limit compliance with study requirements • Any other illness or condition that the treating investigator feels would interfere with study compliance or would compromise the patient’s safety or study endpoints • Known immunodeficiency disease or treatments (HIV) • Known viral or bacterial chronic/acute disease (potential blood borne infections that could result in meningitis or brain abscess) • Coeliac disease or wheat allergy • Known liver dysfunction
- Patients with uncontrolled epilepsy
- Patients with contra-indications to MRI or known sensitivity/allergy to gadolinium, or other intravascular contrast agents
- Known history of hypersensitivity reactions to perflutren lipid microsphere components or to any of the inactive ingredients in Luminity®/Definity®
- Contra indication for sonication
- Patients under judicial protection
- Patients with multifocal tumor (unless all localized in a 70 mm diameter area accessible to ultrasound field) or located in posterior fossa tumor
- Patient with diffuse FLAIR abnormalities attributable to Gliomatosis
- Patients with evidence of uncontrolled intracranial pressure
- Patients with medical need to continue antiplatelet or antithrombotic treatment
- Pregnant or breastfeeding women (blood pregnancy test)
Where in France
Also in 1 other country, 1 site
- Centre Hospitalier Universitaire D'AngersAngers, FranceNot yet recruiting
- Institut de Cancérologie de l'Ouest - site d'AngersANGERS, FranceNot yet recruiting
- Centre Hospitalier Universitaire De BordeauxBordeaux Cedex, FranceNot yet recruiting
- Hospices Civils de LyonBron, FranceNot yet recruiting
- Centre Hospitalier Regional De MarseilleMarseille, FranceNot yet recruiting
- Hopitaux Universitaires Pitie SalpetriereParis, FranceNot yet recruiting
- Hospital FochSuresnes, FranceNot yet recruiting
About the trial
What the trial wants to find out
clinical efficacy based on comparison of median PFS (Progression Free Survival) assessed by local investigator between the standard of care treatment with ultrasound BBB opening versus standard of care treatment alone.
The 2 groups in the trial
- Ultrasound experimental armTreatment being tested
Standard of Care + 15 Ultrasound BBB opening
Treatment: SonoCloud-9 (SC9) device and Temozolomide according Stupp protocol
- Control armOther group
Standard of Care
Treatment: Temozolomide according Stupp protocol
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
- Official title
- Multisite open-label randomized phase II clinical trial in newly diagnosed glioblastoma treated by concurrent TemoRadiation and adjuvant temozolomide +/- ultrasound-induced blood brain barrier opening - SonoFIRST
- Plain-language title
- Tests ultrasound opening the blood-brain barrier with standard treatment for newly diagnosed glioblastomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 5 December 2024